Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals

Synapse

Volumn 66, Issue 11, 2012, Pages 931-937

  Mori, Tomohisa ^a   Shibasaki, Masahiro ^a   Abe, Minako ^a   Udagawa, Yuya ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Dopamine; Dronabinol; Emesis; Morphine; Rewarding effects

Indexed keywords

DOPAMINE; DRONABINOL; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; FERRET; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REWARD; VOMITING;

ANALGESICS, OPIOID; ANIMALS; CANNABINOID RECEPTOR AGONISTS; DOPAMINE; FERRETS; MALE; MICE; MORPHINE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; REWARD; TETRAHYDROCANNABINOL;

EID: 84866171454     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21586     Document Type: Article

References (22)

1. Ayhan IH, Kaymakcalan S, Tulunay FC. 1979. Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice. Psychopharmacology (Berl) 63: 169-172.
2. Cichewicz DL. 2004. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317-1324.
3. Cooper ZD, Haney M. 2009. Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. Int Rev Psychiatry 21: 104-112.
4. Eisenberg E, McNicol ED, Carr DB. 2005. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 293: 3043-3052.
5. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. 2009. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
6. Levin FR, Kleber HD. 2008. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 17: 161-164
7. Narita M, Takahashi Y, Takamori K, Funada M, Suzuki T, Misawa M, Nagase H. 1993. Effects of κ-agonist on the antinociception and locomotor enhancing action induced by morphine in mice. Jpn J Pharmacol 62: 15-24.
8. Narita M, Nagumo Y, Hashimoto S, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T. 2006. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26: 398-405.
9. Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T. 2010. Neuropathic and chronic pain stimuli downregulate central μ-opioid and dopaminergic transmission. Trends Pharmacol Sci 31: 299-305.
10. Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K. 2004. Compartment-specific localization of cannabinoid 1 (CB1) and μ-opioid receptors in rat nucleus accumbens. Neuroscience 127: 101-112.
11. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. 1991. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40: 695-700.
12. Rios C, Gomes I, Devi LA. 2006.μ opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
13. Seltzer Z, Dubner R, Shir Y. 1990. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
14. Shiokawa M, Narita M, Nakamura A, Kurokawa K, Inoue T, Suzuki T. 2007. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. Eur J Pharmacol 570: 108-110
15. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan TPJr. 2001. The cannabinoid agonist WIN55, 212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94: 882-887.
16. Suzuki T, Funada M, Narita M, Misawa M, Nagase H. 1991. Pertussis toxin abolishes mu- and delta-opioid agonist-induced place preference. Eur J Pharmacol 205: 85-88.
17. Suzuki T, Kishimoto Y, Misawa M. 1996. Formalin- and carrageenan-induced inflammation attenuates place preferences produced by morphine, methamphetamine and cocaine. Life Sci 159: 1667-1674.
18. Swegle JM, Logemann C. 2006. Management of common opioid-induced adverse effects. Am Fam Physician 74: 1347-1354.
19. Tanda G, Goldberg SR. 2003. Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms-A review of recent preclinical data. Psychopharmacology (Berl) 169: 115-134.
20. Torigoe K, Nakahara K, Rahmadi M, Yoshizawa K, Horiuchi H, Hirayama S, Imai S, Kuzumaki N, Itoh T, Yamashita A, Shakunaga K, Yamasaki M, Nagase H, Matoba M, Suzuki T, Narita M. 2012. Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain. Anesthesiology 116: 159-169.
21. WHO. 1996. Cancer pain relief. Geneva: World Health Organisation.
22. Woodcock J. 2009. A difficult balance-Pain management, drug safety, and the FDA. N Engl J Med 361: 2105-2107.